Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by DIYGuyon Dec 06, 2017 6:46pm

71 Views

Post# 27105081

Annual meeting rescheduled

CRITICAL OUTCOME TECHNOLOGIES ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS RESCHEDULED

London, ON and Boston, MA (December 6, 2017): Critical Outcome Technologies Inc. (TSX Venture: COT; OTCQB: COTQF)(“COTI” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced a change in the previously set date for the Company’s Annual and Special Meeting of Shareholders (the “Meeting”), which was originally scheduled for Thursday, December 7, 2017 at 9:30 a.m. Eastern Standard Time.

The AGM will now be held on Wednesday, December 20, 2017 at 9:30 a.m. EST at The London Club, Grand Ballroom, 177 Queens Avenue, London, Ontario, N6A 1J1. The record date for determining shareholders entitled to receive notice of and vote at the Meeting remains unchanged.